-
1
-
-
33744899135
-
-
World Health Organization, fact sheet no. 204: hepatitis B. Revised October 2000. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/index.html [accessed 18 May 2005].
-
-
-
-
2
-
-
0029993966
-
Progress towards the comprehensive control of hepatitis B. Introduction
-
Zuckerman A.J. Progress towards the comprehensive control of hepatitis B. Introduction. Gut 38 (1996) S1
-
(1996)
Gut
, vol.38
-
-
Zuckerman, A.J.1
-
3
-
-
0032434467
-
Hepatitis B: a serious public health threat. Viral Hepatitis Prevention Board
-
Grob P., Hallauer J., Kane M., McCloy E., Meheus A., Roure C., et al. Hepatitis B: a serious public health threat. Viral Hepatitis Prevention Board. Vaccine 16 Suppl. (1998) S1-S2
-
(1998)
Vaccine
, vol.16
, Issue.SUPPL
-
-
Grob, P.1
Hallauer, J.2
Kane, M.3
McCloy, E.4
Meheus, A.5
Roure, C.6
-
4
-
-
0037383496
-
-
Geneva, Switzerland; 13-14 September 2002 Consensus statement [short version]
-
EASL Jury. EASL international consensus conference on hepatitis B. Geneva, Switzerland; 13-14 September 2002. J Hepatol 38 (2003) 533-540 Consensus statement [short version]
-
(2003)
J Hepatol
, vol.38
, pp. 533-540
-
-
EASL Jury1
-
5
-
-
27644530137
-
Recombinant hepatitis B vaccines: disease characterization and vaccine production
-
Gellissen G. (Ed), Wiley-VCH, Weinheim
-
Brocke P., Schaefer S., Melber K., Jenzelewski V., Müller F., Dahlems U., et al. Recombinant hepatitis B vaccines: disease characterization and vaccine production. In: Gellissen G. (Ed). Production of recombinant proteins (2005), Wiley-VCH, Weinheim 319-359
-
(2005)
Production of recombinant proteins
, pp. 319-359
-
-
Brocke, P.1
Schaefer, S.2
Melber, K.3
Jenzelewski, V.4
Müller, F.5
Dahlems, U.6
-
6
-
-
0030433396
-
Phase III clinical trial for immunogenicity and safety of a recombinant hepatitis B virus vaccine (HG-II) in the newborn
-
Cho Y.K., Jung Y.S., Yi G.W., Kim Y.O., Choi M.B., Shin S.K., et al. Phase III clinical trial for immunogenicity and safety of a recombinant hepatitis B virus vaccine (HG-II) in the newborn. Korean J Clin Pharmacol Ther 4 (1996) 197-205
-
(1996)
Korean J Clin Pharmacol Ther
, vol.4
, pp. 197-205
-
-
Cho, Y.K.1
Jung, Y.S.2
Yi, G.W.3
Kim, Y.O.4
Choi, M.B.5
Shin, S.K.6
-
7
-
-
0037086485
-
Comparative efficacy, safety and immunogenicity of Hepavax-Gene and Engerix-B, recombinant hepatitis B vaccines, in infants born to HBsAg and HBeAg positive mothers in Vietnam: an assessment at 2 years
-
Hieu N.T., Kim K.H., Janowicz Z., and Timmermans I. Comparative efficacy, safety and immunogenicity of Hepavax-Gene and Engerix-B, recombinant hepatitis B vaccines, in infants born to HBsAg and HBeAg positive mothers in Vietnam: an assessment at 2 years. Vaccine 20 (2002) 1803-1808
-
(2002)
Vaccine
, vol.20
, pp. 1803-1808
-
-
Hieu, N.T.1
Kim, K.H.2
Janowicz, Z.3
Timmermans, I.4
-
8
-
-
33744927206
-
-
Janowicz ZA, Timmermans ITF, Ahn SJ. Hepavax-Gene, a recombinant hepatitis B vaccine: safety and immunogenicity in healthy adults. In: Proceedings of the 10th international congress on infectious diseases [poster presentation].
-
-
-
-
9
-
-
33744946601
-
-
Nguyen TH, Kyung-Ho K, Janowicz Z, Timmermans I. Safety and immunogenicity of Hepavax-Gene, a recombinant hepatitis B vaccine, during the first six years of life, following vaccination at 0, 1 and 2 months. In: Proceedings of the 4th European conference on viral disease [poster presentation].
-
-
-
-
10
-
-
33744920375
-
-
Timmermans ITF, Choi YJ, Kim KH. Summary of clinical experience with recombinant hepatitis B vaccine administered with the 0-1-6 months dosage schedule. In: Proceedings of the 10th international congress on infectious diseases [poster presentation].
-
-
-
-
11
-
-
33744941898
-
-
Berna Biotech Ltd. Data on file.
-
-
-
-
12
-
-
0037159545
-
Global advisory committee on vaccine safety, 20-21 June 2002
-
World Health Organization. Global advisory committee on vaccine safety, 20-21 June 2002. Wkly Epidemiol Rec 77 (2002) 389-394
-
(2002)
Wkly Epidemiol Rec
, vol.77
, pp. 389-394
-
-
World Health Organization1
-
13
-
-
33744945085
-
-
World Health Organization. Statement on thiomersal. Issued August 2003. Available at: www.who.int/vaccine_safety/topics/thiomersal/statement200308/en/ [accessed 5 August 2004].
-
-
-
-
14
-
-
0024435696
-
Vaccination against hepatitis B: comparison of three different vaccination schedules
-
Jilg W., Schmidt M., and Deinhardt F. Vaccination against hepatitis B: comparison of three different vaccination schedules. J Infect Dis 160 (1989) 766-769
-
(1989)
J Infect Dis
, vol.160
, pp. 766-769
-
-
Jilg, W.1
Schmidt, M.2
Deinhardt, F.3
-
15
-
-
0001566476
-
Are booster immunisation needed for lifelong hepatitis B immunity
-
European Consensus Group on hepatitis B immunity
-
European Consensus Group on hepatitis B immunity. Are booster immunisation needed for lifelong hepatitis B immunity. Lancet 355 (2000) 561-565
-
(2000)
Lancet
, vol.355
, pp. 561-565
-
-
-
16
-
-
0038826672
-
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients
-
Gunson R.N., Shouval D., Roggendorf M., Zaajer H., Nicholas H., Holzmann H., et al. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients. J Clin Virol 27 (2003) 213-230
-
(2003)
J Clin Virol
, vol.27
, pp. 213-230
-
-
Gunson, R.N.1
Shouval, D.2
Roggendorf, M.3
Zaajer, H.4
Nicholas, H.5
Holzmann, H.6
-
17
-
-
0001660020
-
Empfehlung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2002
-
STIKO. Empfehlung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2002. Epid Bull RKI 28 (2002) 227-242
-
(2002)
Epid Bull RKI
, vol.28
, pp. 227-242
-
-
STIKO1
|